Tennis Matters: I didn’t see the match-fixing

January 27, 2016

Tennis Matters Blue

Tennis is the latest sport to find itself embroiled in a corruption scandal.  It is not the problem that many observers expected
Leaders We Deserve was and still remains a blog about leadership and its implications in business.  Sport remains a useful way of ‘back engineering’ into business leadership.
In recent months sport has provided a wealth of examples of issues of global institutions failing in the most basic tenets of social corporate responsibility.  LWD subscribers will be able to track back to the most recent in athletics and football.
So now for tennis.  Over the last few weeks a story has developed in a rather predictable way.  First, a suggestion that a few low ranked players were involved in match fixing.
All credit to the BBC who can still produce world class reporting from time to time.
Silence from tennis authorities. The story builds
World number one Novak Djokovic speaks out suggesting it is a minor problem, although he was approached to fix a match early in his career.  First time I was awoken from my slumbers.  Novak was reported as dismissing the claims as sheer speculation.  oh, no  Novak.  Better to have stayed shtum.
More reports that the problem is widespread.
I start preparing this post.
Then an announcement that an official enquiry is to take place.
Tennis Matters
I recently self-published Tennis Matters, a little book of personal anecdotes. One seeded participant at the on-going Australian Open was given a copy to read.  It includes updates of several LWD posts.  I was advised by a legal friend to be careful of one of the posts which suggested there might be a drug problem in tennis.  So I listened to him, but there is still a hint of my concerns in Tennis Matters.
What I didn’t see coming 
What I didn’t see coming was a different sort of scandal.  Over the years there have been curious collapses from winning positions. Players have been fined for not trying.  Perhaps I didn’t want to see any suspicions.  I was more interested in the tensions that impair ‘thinking clearly under pressure’
This story has legs
You can find my slightly redacted comments about drugs in tennis in Tennis Matters.  Until I put out a revised version, this post will have to do.  I have a feeling the story deserves the customary not quite final words … Watch out for updates.
To be continued

10 Headaches for the Drugs Industry

September 22, 2012

GlaxoSmithKline has pleaded guilty and agreed to pay $1 billion in criminal fines and $2 billion in civil fines following a nine-year federal investigation into its activities. The Pharmaceuticals Industry is facing dilemmas which threaten its existence in its current form. Here are ten dilemmas which are keeping executives in Big Pharma organizations awake at night

Onece upon a time, the search for scientific knowledge was associated with contributions to human well-being and enlightened progress. One of the great economists who held that view was Joseph Schumpeter, who also visualised great knowledge-creating laboratories. Such medical laboratories came to pass. Many millions of lives have been saved through their products. Even the humble aspirin was made safely and widely available by such technological processes, as were increasingly sophisticated vaccines and drugs. But today, the firms operating the research laboratories have acquired an increasingly poor image for criminally corrupt business practices.

Their leaders, if they have not resorted to effective drugs, may well spend sleepness nights worrying over the emerging dilemmas

[1] The demise of the ‘funnel’ model of discovery of new drugs. This was the standard business model for finding the next generation of mega-drugs. The model has struggled to retain credibility as fewer financial winners emerged out of the funnel.

[2] Fines for criminal wrongdoings. The global pharmaceutical industry has racked up fines of more than $11bn in the past three years for criminal wrongdoing, including withholding safety data and promoting drugs for use beyond their licensed conditions. In all, 26 companies, including eight of the 10 top players in the global industry, have been found to be acting dishonestly.

[3] The scale of the wrongdoing, revealed for the first time, has undermined public and professional trust in the industry and is holding back clinical progress, according to two papers published in this week’s New England Journal of Medicine [September 2012]

[4] Prosectution of business leaders. Leading lawyers have warned that the multibillion-dollar fines are not enough to change the industry’s behaviour so that criminal prosecutions of executives may be considered more seriously in the near future.

[5] Corporate social responsibilities. The drug companies would like to concentrate on profitable areas and leave research into socially important areas such as alzheimers disease to governmental and other not-for-profit agencies.

[6] Big Pharma’s image problem, fuelled by such high-profile scandals, may have made doctors so suspicious of the industry’s claims that it is warping their clinical judgement

[7] Cynicism of pro-bono efforts. Pressures continue for low-cost drugs delivered to the poorer countries in the world with increasing opportunities for reducing the security of intellectual property such as patents. Industry’s pro-bono efforts are viewed cynically.

[8] Conspiracy theories abound in popular culture. These feed into TV and movie dramas in which leaders of drug companies are part of secret and illegal alliances.

[9] Drug compaies perceived as thoroughly corrupt. Drug companies may be the next industry sector to become increasingly regarded as institutionally corrupt, and its leaders will take their place alongside financial executives, politicians, journalists and the police, in future legal investigations.

[10] More government intervention rather than self-regulation of industry practices will become increasing easy to introduce.

Conspiracy Theory or Leaders We Deserve?

There has been an enormous level of interest in the working of Pharmaceutical Companies as part of a gigantic conspiracy theory. I took a look at the blogs which appeared most prominent via a Google search. The conspiracy theory implies that the big companies are broadly colluding with powerful elites including prominent figures in Governments, the Federal Drug Agency, and in some variants of the theory with other more shadowy groups who meet in clandestine fashion.

One way in which conspiracy theories persist is that they are very difficult to test applying the canons of empirical analysis. That, incidentally, is one interpretation of what a theory is, an abstraction helping to explain the world in which we live.

An alternative abstraction is to consider the wrongdoings in drug companies as episodes to which there is a pattern which does not require the presence of a wider global conspiracy or an ultimate (evil) architect. I like the label of Leaders We Deserve as a start to approaching the means whereby organizations develop their cultures and behaviours.